IKT
Inhibikase Therapeutics, Inc.
$1.59
-2.45%
2026-10-23
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Key Fundamentals
P/E Ratio
4.28
Forward P/E
-4.76
EPS (TTM)
$-0.44
ROE
-52.0%
Profit Margin
0.0%
Price/Book
2.35
Beta
0.96
Market Cap
$287.4M
Avg Volume (10D)
707K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$2.61
60D Low
$1.54
Avg Volume
558K
Latest Close
$1.59
Get breakout alerts for IKT
Sign up for Breakout Scanner to receive daily notifications when IKT triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Inhibikase Therapeutics, Inc. (IKT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IKT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IKT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.